title: Differential roles of orexin receptors within the dentate gyrus in stress- and drug priming-induced reinstatement of conditioned place preference in rats.
abstract: Orexins are hypothalamic peptides involved in the modulation of the feeding, arousal, reward function, learning, and memory; nevertheless, the role of orexins in stress and relapse are largely unclear. Therefore, in the present study, the reinstatement model were used to examine the effects of intradentate gyrus (DG) administration of SB334867 as an orexin-1 receptor antagonist and TCS OX2 29, as an orexin-2 receptor antagonist on drug priming- and forced swim stress (FSS)-induced reinstatement of morphine. One-hundred and 44 adult male albino Wistar rats weighing 200 g-280 g were bilaterally implanted by cannulas into the DG. For induction of conditioned place preference (CPP), subcutaneous (sc) injection of morphine (5 mg/kg) was used daily during a 3-day conditioning phase. Then, the conditioning score (conditional stimulus [CS]) was calculated. After a 24 hr "off" period following achievement of extinction criterion, rats were tested for drug priming-induced reinstatement by priming dose of morphine (1 mg/kg, sc) and for FSS-induced reinstatement 10 min after FSS. In the next experiments, animals received different doses of intra-DG administration of SB334867 and TCS OX2 29 (3, 10, and 30 μg/0.5 μl 12% DMSO per side), bilaterally and were subsequently tested for morphine priming- and FSS-induced reinstatement. Our findings indicated that the FSS-induced the reinstatement of seeking behaviors. Furthermore, intra-DG administration of orexin-1 and orexin-2 receptor antagonists attenuated drug priming-induced reinstatement dose-dependently. However, they have trivial role in FSS-induced reinstatement. It is concluded that drug priming-induced reinstatement may be mediated, at least in part, by stimulation of orexin receptors in the DG.
authors.affiliation: Department of Physiology, Ahvaz Jondishapur University of Medical Sciences.
authors.forename: Fereshte
authors.initials: F
authors.lastname: Ebrahimian
authors.affiliation: Neuroscience Research Center, Shahid Beheshti University of Medical Sciences.
authors.forename: Farzaneh Sadat
authors.initials: FS
authors.lastname: Naghavi
authors.affiliation: Neuroscience Research Center, Shahid Beheshti University of Medical Sciences.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Yazdi
authors.affiliation: Neuroscience Research Center, Shahid Beheshti University of Medical Sciences.
authors.forename: Fatemeh
authors.initials: F
authors.lastname: Sadeghzadeh
authors.affiliation: Department of Physiology, Hamadan University of Medical Sciences.
authors.forename: Zahra
authors.initials: Z
authors.lastname: Taslimi
authors.affiliation: Neuroscience Research Center, Shahid Beheshti University of Medical Sciences.
authors.forename: Abbas
authors.initials: A
authors.lastname: Haghparast
mesh_terms: D000701:Analgesics, Opioid / Q000008:administration & dosage; D000818:Animals; D001583:Benzoxazoles / Q000494:pharmacology; D003216:Conditioning, Operant / Q000187:drug effects / Q000502:physiology; D003213:Conditioning, Psychological / Q000187:drug effects / Q000502:physiology*; D018891:Dentate Gyrus / Q000187:drug effects / Q000502:physiology*; D004305:Dose-Response Relationship, Drug; D058999:Drug-Seeking Behavior / Q000187:drug effects / Q000502:physiology; D005108:Extinction, Psychological; D007546:Isoquinolines / Q000494:pharmacology; D008297:Male; D009020:Morphine / Q000008:administration & dosage; D009287:Naphthyridines; D000068796:Orexin Receptor Antagonists / Q000494:pharmacology; D064446:Orexin Receptors / Q000378:metabolism*; D011725:Pyridines / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D012201:Reward; D013315:Stress, Psychological / Q000503:physiopathology*; D013550:Swimming / Q000523:psychology; D013997:Time Factors; D014508:Urea / Q000031:analogs & derivatives / Q000494:pharmacology
chemical_list: C420062:1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea; C572065:1-(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)-3,3-dimethyl-2-((4-pyridinylmethyl)amino)-1-butanone; D000701:Analgesics, Opioid; D001583:Benzoxazoles; D007546:Isoquinolines; D009287:Naphthyridines; D000068796:Orexin Receptor Antagonists; D064446:Orexin Receptors; D011725:Pyridines; D009020:Morphine; D014508:Urea